Clinical Trial Search

Primary: A Composite of the Total Number of Participants With Either Tachycardia Change or Tachycardia Termination With First Ablation Set. — 38; 29 Participants

Primary: Chronic Effectiveness — 56; 26 percentage of participants with success — p=<0.0001

Primary: Unplanned Hospital Admissions for Cardiac Reasons OR Death of Cardiovascular Causes OR Progression to Chronic Atrial Fibrillation — 43; 44 participants

Primary: Number of Patients With Atrial Thrombus and a Zero ATE Score — 2; 816; 27; 2227 Participants

Primary: The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration. — 135.5; 130.3; 130.7; 95.2 bpm — p=<0.0001

Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG

Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants

Primary: Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE) — 32; 32; 15; 15 participants — p=<0.0001

Primary: Primary Safety: Incidence of Composite, Serious Adverse Events Within 7 Days Post-Procedure — 5 participants

Primary: Time to Imaging — 28.1; 7.1 hours

Primary: To Define the Normal Range of Voltage Amplitude — 2.00; 1.92 mV

Primary: Percent of Patients Free From AF and Off Class I and III Anti-arrhythmic Drugs as Determined by Holter Monitoring at 6 Months. — 74 percentage of subjects

Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants

Primary: Percentage of Participants With Primary Adverse Events (PAEs) — 0.0; 0.0; 1.5; 1.5 percentage of participants

Primary: Freedom From Any Atrial Arrhythmias — 24; 23 Participants — p=.83

Primary: The Number of Patients With First Dose Successful Termination of the Supraventricular Tachycardia to a Sinus Rhythm of Less Than 140 With the AHA Versus a Simplified…

Primary: Atrial Fibrillation Burden — 2; 8.5 Percent time spent in atrial fibrillatio

Primary: Freedom From Recurrence of Symptomatic Atrial Fibrillation, Atrial Tachycardia or Atrial Flutter — 99; 93 participants

Primary: Pivotal Main Phase Modified Intent-To-Treat (mITT) Analysis Set: Number of Participants With Primary Adverse Events (PAEs) — 8 Participants

Primary: Efficacy of Anti Tachycardia Pacing (ATP) Therapy to Terminate Fast Ventricular Tachycardia (With Cycle Length of 240ms-320msec) — 64.9; 69.7 Percentage of FVT episodes…

Primary: Safety at 30 Days — 1 Participants

Primary: Change in AF Burden — -0.4; -2.4 percentage of time in AF

Primary: Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT) — 16; 29 Participants

Primary: Dose-response Relationship for QTcF Interval of AZD1305 — 461; 486; 490; 482 ms

Primary: Rate of Serious Adverse Events — 7 Participants — p=<0.0001

Primary: Number of Participants With Device or Procedure-related Serious Adverse Events — 12; 2 Participants

Primary: Percentage of Patient With Atrial Fibrillation Termination at the End of the Procedure — 95; 60 Percentage of participants

Primary: Atrial Fibrillation (AF) Burden Defined as the Mean Amount of Time Spent in AF Over a Pre-specified Period of Time (Excluding Short AF Episodes of ≤30 Seconds) by the…

Primary: Number of Participants Free From Documented AF After One Ablation Procedure — 158; 124 Participants

Primary: The Percentage of Chronic Success of the NAVISTAR THERMOCOOL Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (PAF) — 66; 16 Percentage of…